Abstract 1814
Background
Tumor Treating Fields (TTFields) are intermediate frequency, alternating electric fields that non-invasively treat cancer. Transducer arrays positioned on the skin in proximity to the targeted tumor transmit TTFields. A post-hoc analysis [Ballo et al. Red Jour. 2019 In Press] has shown that increased patient usage (percent of time on active treatment) and intensity of TTFields delivery direct to the tumor improved survival. Optimal array positioning may enhance TTFields intensity at the tumor site to improve patient experience and survival. Minimization of array exposure area would enhance patient comfort levels and usage to improve survival. Optimizing TTFields delivery and distribution depends on array positioning and geometry, patient anatomy, and the heterogeneous electrical properties of different tissues. We present methodology to optimize TTFields delivery using numerical simulations.
Methods
TTFields delivery to the brain, lung, and abdomen utilizing representative computational models was investigated. The effects of transducer array size and position on field distribution within the phantoms was analyzed, and an approach to optimize TTFields delivery was developed.
Results
Field intensity was typically the greatest in between arrays, with larger arrays transmitting higher field power. Anatomical features, such as bones (spine) or a resection cavity significantly influenced field intensity within this region. A generalized methodology to optimize TTFields delivery for improved patient care was based on: (1) Striking a balance between maximal field intensity (largest arrays feasible) and minimal skin exposure to arrays in the disease area; (2) Positioning virtual arrays on a representative, computational patient model to test tumor localization between arrays, to simulate TTFields delivery to patient, and to assess optimal delivery; and (3) Applying an iterative algorithm to shift arrays around their initial positions until field intensity is maximized directly to the tumor bed.
Conclusions
A generalized treatment methodology as presented by these data will optimize TTFields delivery to the tumor site. Effective TTFields treatment planning is expected to improve patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novocure.
Funding
Novocure.
Disclosure
N. Urman: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. Z. Bomzon: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. H.S. Hershkovich: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E.D. Kirson: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. A. Naveh: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. R. Shamir: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E. Fedorov: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. C. Wenger: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. U. Weinberg: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract